Liina Viitas OÜ
- Address
- Veetorni 2-1, 80018 Pärnu, Estonia
Cardiovascular Disease Prevention Research Center
Liina Viitas OÜ is a clinical research facility specializing in cardiovascular disease prevention and treatment. The center focuses on evaluating innovative therapeutic approaches for patients at high risk of developing atherosclerotic cardiovascular disease, with particular emphasis on primary prevention strategies that can reduce major adverse cardiovascular events before they occur.
- Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
- Major adverse cardiovascular events (MACE) reduction strategies
- Novel lipid-lowering therapies and cardiovascular risk management
The center conducts sophisticated randomized, double-blind, placebo-controlled trials designed to demonstrate the efficacy of emerging treatments in preventing cardiovascular death, myocardial infarction, ischemic stroke, and urgent coronary revascularization. Their research contributes to advancing preventive cardiology and identifying new approaches to protect high-risk patients from life-threatening cardiovascular complications.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Eli Lilly & Co.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Liina Viitas OÜ
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Orforglipron on Major Adverse Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease | Eli Lilly & Co. | Phase III | Recruiting | May 2026 | — |
IMP list
lock Showing 1 of 7 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 3 | Unknown | 2021-11-26 | 2022-04-08 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.